Sharemaestro company-news research for Roche Holding AG (RHO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
GER
Germany
Provisional evidence
Company news sentiment
Latest RHO news and sentiment
Roche Holding AG
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
30 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone61/100
→
Published 30-day score50/100
Latest source headline
What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?
finance.yahoo.com · 01 Oct 2026 20:08
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
30 current stories are mapped specifically to RHO.
The score uses 5 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.022.
Confidence is 14/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
14/100
Confidencethin evidence
78%/100
Company news30 company stories
96/100
Story agreement4/100 difference
News history
Daily score and story count over 30 days
08 Sep23 Sep07 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.022 after freshness weightingSource breadth100
5 independent publishersCompany relevance78
share tied directly to this companyFreshness12
recency-weighted evidenceAgreement96
how closely stories agreePublisher mix52
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202650EUR 381.799988-3.7%
25 Sep 202651EUR 396.399994+2.6%
18 Sep 202652EUR 386.399994+3.5%
11 Sep 202651EUR 373.200012-3.5%
04 Sep 202652EUR 386.600006-1.4%
28 Aug 202655EUR 392.0-3.5%
21 Aug 202652EUR 406.200012+5.6%
14 Aug 202655EUR 384.600006-3.7%
Provisional evidence
News subjects
What is shaping the score
Market update5320 stories · 67%
Earnings535 stories · 17%
Regulatory and legal503 stories · 10%
Analyst action501 stories · 3%
Deals and strategy501 stories · 3%
Source mix
Where the evidence comes from
GlobeNewswire508 stories · 27%
finance.yahoo.com535 stories · 17%
InvestorsHub573 stories · 10%
Simply Wall St.533 stories · 10%
BioPharma Dive512 stories · 7%
The Wall Street Journal492 stories · 7%
Zacks502 stories · 7%
Recurring subjects
Subjects appearing most often
Clinical Trials14Pharma10Biotech9Shareholder7Fda Approval6Healthcare5Obesity3R D2Oncology2Market Research Reports2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
25 Jun50 neutral07 Oct 01:50
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 07 Oct 01:50 | 50 | +0 | 14/100 (-2) | 30 (-4) | Provisional |
| 01 Oct 23:59 | 50 | -1 | 16/100 (-2) | 34 (0) | Provisional |
| 28 Sep 23:59 | 51 | +0 | 18/100 (-1) | 34 (+1) | Provisional |
| 27 Sep 23:59 | 51 | -1 | 19/100 (-5) | 33 (-4) | Provisional |
| 24 Sep 23:59 | 52 | +0 | 24/100 (-3) | 37 (0) | Provisional |
| 23 Sep 23:59 | 52 | +0 | 27/100 (-1) | 37 (+9) | Provisional |
| 22 Sep 23:59 | 52 | +0 | 28/100 (+3) | 28 (+3) | Provisional |
| 21 Sep 23:59 | 52 | +0 | 25/100 (-1) | 25 (-1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 30 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings2 stories
0.0%92.1%
Market update5 stories
2.6%5.3%
Each side uses the same scale: 0–92.1% of the retained directional evidence.
Where the influence comes from
62.7%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?
Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutin…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutinib could become the first high efficacy oral BTK inhibitor targeting both relapse control and disability progression in MS. The FDA's priority review for fenebrutinib in relapsing and primary progressive MS is a key development to weigh against the rest of our analysis. Our analysis turns up 1 warning sign for
- Published
- 01 Oct 2026 20:08
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetBiotechClinical TrialsFda ApprovalPharmaRegulation
—Unscored
EarningsNot used in direction
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add anothe…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche's efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with companies including AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) racing to develop new tr
- Published
- 28 Sep 2026 19:55
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsObesityPharma
—Unscored
EarningsNot used in direction
Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships
Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche a…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and obesity, highlighting Roche's GLP-1/GIP pipeline ambitions. These new AI-driven alliances and CT-388 Ph
- Published
- 27 Sep 2026 20:06
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AIDrug DiscoveryHealthcareMetabolic DiseaseOncology
—Unscored
Market updateNot used in direction
Roche targets Novartis on IgAN market after Phase III win
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 17:06
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues
Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question fo…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current valuation story. Recent phase III successes with partners like MediLink and Ionis, along with regulatory
- Published
- 23 Sep 2026 23:14
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Clinical TrialsEarningsPharmaShare PriceShareholderValuation
—Unscored
Market updateNot used in direction
Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?
Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than fading. Capitalize on the momentum around Roche Holding and this latest clinical win by scanning a hand
- Published
- 23 Sep 2026 19:14
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetBiotechClinical TrialsDividendsIntrinsic ValuePharma
—Unscored
Market updateNot used in direction
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. depositary receipts slipped about…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. depositary receipts slipped about 1.0% to $55.11. At that price, Roche trades 33.15% above its $41.39 GF Value. Investors are paying a premium even as this drug's longer-term benefits remain unproven. Warning! GuruFocus has detected 7 Warning Signs with RHHBY. Is RHHBY fairly valued? Test your thesis with our free DCF calculator.RHHBY GF Valu
- Published
- 23 Sep 2026 18:06
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsPharma
—Unscored
Market updateNot used in direction
Roche, Ionis RNA drug scores in kidney disease study
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 16:21
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Roche’s Sefaxersen Meets Primary Endpoint in Phase III Kidney Disease Trial
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 10:17
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.9d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Company Logo Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring - Global Strategic Busine…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Company Logo Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Therapeutic Drug Monitoring was estimated at US$1.5 Billion in 2025 and is projected to reach US$2.6 Billion by 2032, growing at a CAGR of 8.3% from 2025 to 2032. This comprehensive report provides an in-depth analysis of mar
- Published
- 23 Sep 2026 08:11
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
AI SoftwareChronic DiseaseHealthcareMarket Research ReportsPersonalized MedicinePharmacogenomics
—Unscored
Market updateNot used in direction
Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 07:53
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 06:11
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
57/100 tone
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary …
2.5% of directional evidence
Low story strength
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1 IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation2-4 Interim data will be presented at an upcom
- Published
- 23 Sep 2026 05:15
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 2.5% of directional evidence · 14.2d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Autoimmune DiseaseBiotechClinical TrialsKidney DiseaseNephrologyPharma
—Unscored
Market updateNot used in direction
Change in Roche’s Board of Directors
F. Hoffmann-La Roche Ltd Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. Roche Chairman Sev…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan: "I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe's intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen our Board." About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare
- Published
- 23 Sep 2026 05:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
HealthcareShareholder
—Unscored
Regulatory and legalNot used in direction
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
Roche RHHBY reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints at 48 weeks, delivering…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche RHHBY reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight. The encouraging results strengthen Roche's prospects of establishing a foothold in the rapidly expanding obesity and metabolic disease market. Year to date, shares of Roche have risen 9.8% compared with the industry's rise of 7%.Zacks Investment Research Ima
- Published
- 22 Sep 2026 19:32
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Clinical TrialsDiabetesObesityPharma
43/100 tone
2.6% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 22 Sep 2026 05:32
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 2.6% of directional evidence · 15.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
F. Hoffmann-La Roche Ltd At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reductio…
62.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of ≤6.5% HbA1c, while 62% achieved normoglycemia (HbA1c < 5.7%) At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau Enicepatide demonstr
- Published
- 22 Sep 2026 05:00
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 41/100
- 30-day weight
- 62.7% of directional evidence · 15.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechnologyCardiovascular DiseaseClinical TrialsGlp 1 Receptor AgonistObesityShareholder
67/100 tone
F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3 Susvimo helps people with nAMD maintain …
2.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3 Susvimo helps people with nAMD maintain their vision with as few as two treatments per year1-3 Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections2 nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European
- Published
- 21 Sep 2026 15:45
- News subject
- Market update
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 2.2% of directional evidence · 15.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Clinical TrialsFda ApprovalOphthalmologyPharmaShareholder
—Unscored
Regulatory and legalNot used in direction
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
F. Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1 Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA)
- Published
- 18 Sep 2026 10:45
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsFda ApprovalNeurologyPharmaShareholder
—Unscored
Deals and strategyNot used in direction
Roche agrees to $1bn deal with Dualitas for bispecific antibody research
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 18 Sep 2026 09:29
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
F. Hoffmann-La Roche Ltd The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche's and Genentech's prese…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche's and Genentech's presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs This is part of Roche and Genentech's USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon Base
- Published
- 17 Sep 2026 18:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Drug DiscoveryHealthcareInnovationLife SciencesR DShareholder
—Unscored
Market updateNot used in direction
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to advance drug discovery and development Innovation Center is part of Roche and Genentech's $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina and Hillsboro, Oregon SOUTH SAN FRANCISCO, Calif., September 17, 2026--(BU
- Published
- 17 Sep 2026 18:30
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
AIBiotechData ScienceInnovationR D
—Unscored
Market updateNot used in direction
Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma
Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio's label to patients who have received at least one…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio's label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for Lunsumio and lenalidomide signals a broader story investors should weigh beyond this single trial update.
- Published
- 17 Sep 2026 15:11
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Clinical TrialsOncologyPharma
57/100 tone
29.4% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 14:25
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 29.4% of directional evidence · 19.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
59/100 tone
0.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 06:00
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.3% of directional evidence · 20.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
58/100 tone
Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinfo…
0.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health authorities and presented at an upcoming medical meeting SOUTH SAN FRANCISCO, Calif., September 17, 202
- Published
- 17 Sep 2026 05:00
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 28/100
- 30-day weight
- 0.3% of directional evidence · 20.2d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechClinical TrialsFda ApprovalHealthcareHematology OncologyLymphoma
—Unscored
F. Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 T…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
F. Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink's proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3 Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong,
- Published
- 13 Sep 2026 00:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsFda ApprovalLung CancerShareholder
—Unscored
Regulatory and legalNot used in direction
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). With the FDA granting a priority review to the sB…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Jan. 10, 2027. MOGAD is a rare autoimmune disease of the central nervous system that can cause unpredictable attacks affecting the optic nerves, spinal cord or brain. If approved, Enspryng would become the first and only disease-modifying therapy for MOGAD
- Published
- 10 Sep 2026 15:42
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsEarnings Per ShareFda Approval
—Unscored
Market updateNot used in direction
Roche’s Genentech Gets FDA Priority Review for Enspryng in MOGAD
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 10 Sep 2026 14:35
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Company Logo 249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With Confidence Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Markets. Strategy & Trends with F…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Company Logo 249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With Confidence Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Markets. Strategy & Trends with Forecasts by Assay Type, by Animal, by Application, by Place, by Product, and by Country 2026 to 2030" report has been added to ResearchAndMarkets.com's offering. The Veterinary Diagnostics industry is on a strong growth path driven by fundamental shifting patterns in animal ownership and management. Learn all
- Published
- 07 Sep 2026 10:38
- News subject
- Market update
- Why this score
- Operating growth
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Animal HealthDiagnostic TestingMarket Research ReportsPet CareVeterinary DiagnosticsVeterinary Medicine
Earlier company news
RHO news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 35 older RHO headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to RHO, but the headline and available text are not mainly about Roche Holding AG. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of RHO sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.